P004: Bone Health and Oncology Support

P004 is an innovative biosimilar designed to strengthen bone density and prevent fractures in patients with bone metastases and osteoporosis. By inhibiting bone resorption, P004 helps protect skeletal health, particularly for cancer patients and individuals at high risk of bone-related complications. With its competitive pricing and robust clinical backing, P004 is set to become a cornerstone therapy in oncology and bone health management.